Tamoxifen

• Exploratory study to evaluate the safety and tolerability of tamoxifen citrate in the treatment of cystic fibrosis in patients without mutat… Pending
  2024-519657-11-00 Phase II 1 country Azienda Ospedaliera Universitaria Integrata Verona
• ENDO-67 project: Investigating ENDOcrine therapy-related questions using Ki67 changes in the window-of-opportunity before breast surgery Pending
  2025-521385-10-00 Phase IV 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• Skipping Hormone Therapy in Low-Risk Early Breast Cancer Pending
  2025-523683-20-00 Phase II 1 country Unicancer
• Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Recruiting
  2024-519655-28-00 Phase III 7 countries Unicancer
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting
  2024-515445-42-00 Phase III 15 countries Stemline Therapeutics Inc.
• The POWER trial: A randomised, two-armed open label phase 3 clinical trial on personalised dose optimisation with adjuvant tamoxifen therapy… Recruiting
  2025-522240-40-00 Phase III 1 country Karolinska Institutet
• Optimizing endocrine treatment > 5 years after surgery for breast cancer patients: a registry-based randomized clinical trial Recruiting
  2023-506135-14-00 Phase III/IV 1 country Region Oerebro Laen
• Evaluating how well and how safely Alisertib works with hormone therapy in treating patients with breast cancer that has come back or spread… Recruiting
  2024-511497-79-00 Phase II 2 countries Puma Biotechnology Inc.
• The RED FLASH study Recruiting
  2023-507847-13-00 Phase III 1 country Reinier de Graaf Groep
• An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi… Recruiting
  2022-501453-36-00 Phase III 11 countries European Organisation For Research And Treatment Of Cancer
• ExclUsive endocRine therapy Or radiation theraPy for women aged ≥70 years with luminal A-like early stage breast cancer (EUROPA): a randomiz… Recruiting
  2023-508094-88-00 Phase III 1 country University Of Florence
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac… Ended
  2022-502046-28-00 Phase III 7 countries F. Hoffmann-La Roche AG
• A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsore… Ended
  2024-514891-41-00 Phase IV 5 countries Novartis Pharma AG
• A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versu… Ended
  2022-500014-26-00 Phase III 8 countries F. Hoffmann-La Roche AG
• A Phase II study of post-operative palbociclib as an alternative to chemotherapy in older patients with localized breast cancer at high risk… Ended
  2023-505223-31-00 Phase II 7 countries European Organisation For Research And Treatment Of Cancer
• PREDIX Luminal B - Neoadjuvant response-guided treatment of estrogen receptor positive tumors with high proliferation or slow proliferation … Ended
  2024-519019-32-00 Phase II 1 country Karolinska University Hospital
• "A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone… Ended
  2024-515368-29-00 Phase III 1 country Fundacion Grupo Espanol De Investigacion En Cancer De Mama
• SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endrocrine Therapy +/- Chemotheraphy in Patients with 1-3 Positive N… Ended
  2024-516801-22-00 Phase III 1 country Cancer Trials Ireland
• PREOPERATIVE WINDOW OF OPPORTUNITY STUDY WITH GIREDESTRANT (GDC-9545) OR TAMOXIFEN IN PREMENOPAUSAL WOMEN WITH ER[+]/HER2[-] & KI67≥10% EARL… Ended
  2023-503565-36-00 Phase II 2 countries Medica Scientia Innovation Research S.L.
• Study to evaluate the effect of metformin in the prevention of hyperglycemia in HR[+]/HER2[–] PIK3CA-mutated advanced breast cancer patients… Ended
  2024-511295-33-00 Phase II 1 country Medica Scientia Innovation Research S.L.

Showing 1–20 of 20 trials